EKF Diagnostics Holdings plc
("EKF" or the "Company")
Exercise of options and Total Voting Rights
Exercise of options
EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted point-of-care business, announces that it has issued and allotted 500,000 ordinary shares of one pence each in the share capital of the Company ("Ordinary Shares") following an exercise of options on 5 May 2020. The exercise price was 20 pence per Ordinary Share.
Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 500,000 new Ordinary Shares to trading on AIM will become effective on, or around, 13 May 2020 ("Admission").
Total voting rights
Following Admission, the Company will have 454,593,227 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 454,593,227.
Enquiries:
|
EKF Diagnostics Holdings plc |
||
|
Christopher Mills, Non-Executive Chairman |
Tel: 029 2071 0570 |
|
|
Julian Baines, CEO |
|
|
|
Richard Evans, FD & COO |
|
|
|
|
|
|
|
N+1 Singer (Nomad & Broker) |
Tel: 020 7496 3000 |
|
|
Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate Finance) Tom Salvesen (Corporate Broking) |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus/ Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.